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Abstract
Systemic sclerosis (SSc) is characterized by excessive fibrosis of the skin and internal organs due to fibroblast proliferation
and excessive production of extracellular matrix (ECM). We have shown that insulin-like growth factor binding protein
(IGFBP)-5 plays an important role in the development of fibrosis in vitro, ex vivo, and in vivo. We identified a membrane-
associated adaptor protein, downstream of tyrosine kinase/docking protein (DOK)5, as an IGFBP-5-regulated target gene
using gene expression profiling of primary fibroblasts expressing IGFBP-5. DOK5 is a tyrosine kinase substrate associated
with intracellular signaling. Our objective was to determine the role of DOK5 in the pathogenesis of SSc and specifically in
IGFBP-5-induced fibrosis. DOK5 mRNA and protein levels were increased in vitro by endogenous and exogenous IGFBP-5 in
primary human fibroblasts. DOK5 upregulation required activation of the mitogen-activated protein kinase (MAPK) signaling
cascade. Further, IGFBP-5 triggered nuclear translocation of DOK5. DOK5 protein levels were also increased in vivo in mouse
skin and lung by IGFBP-5. To determine the effect of DOK5 on fibrosis, DOK5 was expressed ex vivo in human skin in organ
culture. Expression of DOK5 in human skin resulted in a significant increase in dermal thickness. Lastly, levels of DOK5 were
compared in primary fibroblasts and lung tissues of patients with SSc and healthy donors. Both DOK5 mRNA and protein
levels were significantly increased in fibroblasts and skin tissues of patients with SSc compared with those of healthy
controls, as well as in lung tissues of SSc patients. Our findings suggest that IGFBP-5 induces its pro-fibrotic effects, at least
in part, via DOK5. Furthermore, IGFBP-5 and DOK5 are both increased in SSc fibroblasts and tissues and may thus be acting
in concert to promote fibrosis.
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Introduction
Systemic sclerosis (SSc) is characterized by excessive organ
fibrosis due to fibroblast proliferation and production of extracel-
lular matrix (ECM) [1]. Our group previously reported increased
expression of insulin-like growth factor binding protein (IGFBP)-5
in primary early-passage dermal fibroblasts cultured from patients
with SSc [2]. We also reported that IGFBP-5 mRNA and protein
levels are increased in vivo in lung tissues of patients with idiopathic
pulmonary fibrosis (IPF) and in vitro in primary fibroblasts cultured
lung tissues of patients with SSc and those with IPF [3,4].
Interestingly, IGFBP-5 triggers a fibrotic phenotype in vitro [3] and
in vivo [4,5] that includes induction of ECM production, myofi-
broblastic transformation and infiltration of mononuclear cells [6].
Furthermore, IGFBP-5 induces dermal fibrosis in human skin
maintained in organ culture [7]. These findings suggest that
IGFBP-5 is responsible, at least in part, for the fibrosis
characteristic of SSc.
We used gene expression profiling of primary fibroblasts
expressing IGFBP-5 to identify downstream effectors of IGFBP-5
and found a membrane-associated adaptor protein, downstream of
tyrosine kinase/docking protein (DOK)5, as an IGFBP-5 target
gene. DOK5 belongs to the docking family of proteins that contain
tandem pleckstrin homology-phosphotyrosine binding (PH-PTB)
domains at their amino termini [8]. DOK proteins are also known
as insulin receptor substrates (IRS) and serve as substrates for
insulin and insulin-like growth factor [9] as well as various protein
tyrosine kinases [10,11]. DOK5 functions as a specific signal
transduction molecule and plays an important role in cellular
differentiation [11,12]. Our goal was to assess the levels of DOK5
in fibrotic tissues from patients with SSc and to delineate the role
of DOK5 in IGFBP-5-induced fibrosis.
Materials and Methods
Lung and Skin Samples
Human skin was obtained from corrective plastic surgery and
maintained in organ culture as we have previously reported [7,13].
Skin punch biopsies were obtained from the clinically affected and
unaffected skin of patients with SSc as we have previously
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described [2]. Lung tissues were obtained from the explanted lungs
of patients with SSc-associated pulmonary fibrosis who underwent
lung transplantation at the University of Pittsburgh Medical
Center, and normal donors whose lungs were not used for
transplantation as previously reported [14,15]. All tissues were
obtained under a protocol approved by the Institutional Review
Board of the University of Pittsburgh and following written
informed consent. Relevant information on the patients with SSc
is summarized in Tables 1 & 2.
Primary Fibroblast Culture
Human primary lung and skin fibroblasts were cultured from
the explanted lungs of normal organ donors or the skin of healthy
controls under a protocol approved by the University of Pittsburgh
Institutional Review Board. Primary fibroblasts were also cultured
from the skin of twins discordant for SSc. Approximately 2–3 mm2
pieces of tissue were minced and fibroblasts were cultured in
Dulbecco’s modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), penicillin, streptomycin, and anti-
mycotic agent, as previously described [3]. All cells were used
between passages 4–6.
Adenovirus Construct Preparation
Adenovirus constructs were obtained as previously reported [3].
Briefly, the full-length cDNAs of human DOK5, IGFBP-3 and
IGFBP-5 were obtained by reverse transcriptase-polymerase chain
reaction (RT-PCR) using total RNA extracted from primary
human fibroblasts. The cDNAs were subcloned into the shuttle
vector pAdlox and used for the preparation of replication-deficient
adenovirus serotype 5 expressing DOK5 (DOK5 AdV), IGFBP-3
(IGFBP-3 AdV), IGFBP-5 (IGFBP-5 AdV), or no cDNA (Control
AdV) in the Vector Core Facility of the University of Pittsburgh.
In Vivo Experiments
Administration of adenovirus to mice was done as previously
described [4,5]. All studies and procedures were approved by the
University of Pittsburgh Institutional Animal Care and Use
Committee. All efforts were made to minimize suffering. Wild-
type C57BL/6J mice were intratracheally or intradermally
injected with Control AdV, DOK5 AdV, IGFBP-5 AdV or
IGFBP-3 AdV. Mice were sacrificed 8 days post adenoviral
administration. Harvested lung and skin tissues were fixed with
10% formalin and embedded in paraffin.
Preparation of Nuclear and Cytoplasmic Extracts
Nuclear and cytoplasmic extracts were prepared as previously
reported [16]. Briefly, 1.26106 fibroblasts were cultured on 10-cm
dishes and scraped with Buffer A (10 mM HEPES-KOH pH 7.9,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF).
Lysates were incubated on ice for 10 minutes. After centrifugation
at 12,000 rpm for 30 seconds, supernatant (cytoplasmic extract)
was harvested. The pellet was resuspended in Buffer C (20 mM
HEPES-KOH pH7.9, 25% glycerol, 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF) and
incubated on ice for 20 minutes. After centrifugation at
12,000 rpm for 30 seconds, nuclear extracts were harvested and
used for immunoblotting.
Preparation of Lung Homogenates
Lung tissues were weighed and homogenized with a tissue
homogenizer in 10 volumes of RIPA buffer with protease inhibitor
and 0.5% Triton-X. Following centrifugation (13,0006g at 4uC
for 30 minutes), the supernatant was collected. Samples were
mixed with sample buffer containing SDS and used for
immunoblotting.
Immunohistochemistry and Immunocytostaining
For immunohistochemistry, sections of paraffin-embedded lung
tissues were de-paraffinized, and endogenous peroxidase and
biotin were quenched. For immunocytostaining, fibroblasts were
cultured on cover slips coated with type I collagen. Sections or
cover glasses were blocked with 5% serum and incubated with
anti-DOK5 antibody followed by secondary antibody. Bound
secondary antibody was detected using the AEC Red kit or
Fluorescence detection kit. A light hematoxylin counterstain
(immunohistochemistry) and DAPI or TO-PRO-1 (Molecular
Probes, Eugene, OR) was used to identify nuclei. Images were
taken on a Nikon Eclipse 800 microscope or Olympus Fluoview
1000 using identical camera settings. Intensity of signal was
examined using MetaMorphH software.
Immunoblotting
Fibroblasts were cultured in medium supplemented with
500 ng/ml recombinant human IGFBP-5 or 5ml 10 mM HCl as
a vehicle control. For adenoviral infection, fibroblasts were
transduced with Control AdV, DOK5 AdV, IGFBP-5 AdV or
IGFBP-3 AdV at an MOI of 50. Culture supernatants and cellular
lysates were harvested and analyzed by immunoblotting. Signals
were detected following incubation with horseradish peroxidase-
conjugated secondary antibody and chemiluminescence.
Table 1. Description of SSc patients from whom skin biopsies were obtained.
Patient code Age (yrs) Gender
Disease duration
(yrs) Disease type Auto-antibody
Treatment (at the time of
biopsy)
SSc-101 41.8 Male 8.1 Diffuse RNA pol, PL-12 Prednisone, Penicillamine,
Methotrexate
SSc-102 38.6 Female 0.7 Diffuse RNA pol None
SSc-103 67.2 Female 0.9 Diffuse N/A Methotrexate
doi:10.1371/journal.pone.0087754.t001
Table 2. Description of SSc patients from whom lung tissues
were obtained.
Lung Sample Age (yrs) Gender Histology
SSc-24 45.1 Male UIP/NSIP
SSc-26 57.5 Male UIP
SSc-30 58.8 Female UIP
doi:10.1371/journal.pone.0087754.t002
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Detection of DOK5 mRNA
DOK5 and b-actin mRNA expression in cultured fibroblasts
was detected using RT-PCR. Primer sets were forward: 59-
CACGGATCAATGACATCAGC-39, reverse: 59-TCA-
GAGGGCTGGAAACATCT-39 to amplify DOK5 (534 bp) and
forward: 59-ATGTTTGAGACCTTCAACAC-39, reverse: 59-
CACGTCACACTTCATGATGG-39 to amplify b-actin
(494 bp). PCR conditions were 3 min at 94uC, followed by 35
(for DOK5) or 30 (for b-actin) cycles of 1 min at 94uC, 1 min at
60uC, and 1 min at 72uC. PCR products were separated by
electrophoresis on agarose gels and stained with ethidium
bromide.
Ex Vivo Human Skin Culture
Human skin culture was done as previously reported [7,13].
Briefly, skin tissue obtained from plastic surgery was cut into
1.5 cm61.5 cm sections and subcutaneous fat was trimmed.
16108 pfu AdV were injected intradermally. Dermal layers were
cultured in an air liquid interface with the epidermal layer side up
and exposed to air. DMEM supplemented with 10% FBS,
penicillin, streptomycin, and anti-mycotic agent was replaced
daily. Skin tissue was harvested and fixed in 10% formalin prior to
embedding in paraffin.
Figure 1. DOK5 expression is upregulated by endogenous and exogenous IGFBP-5 via MAPK. A. DOK5 mRNA is upregulated by
endogenous IGFBP-5. Human skin fibroblasts were infected with adenovirus expressing IGFBP-3, IGFBP-5 or control (IGFBP-3 AdV, IGFBP-5 AdV, or
control AdV, respectively) at an MOI of 50. Expression of DOK5 was examined by RT-PCR. b-actin is shown as a loading control. Results are
representative of two independent experiments using different fibroblast strains. B. Production of DOK5 protein is induced by endogenous IGFBP-5.
Production of DOK5 was examined by immunoblotting in whole cell lysates treated as in A. Molecular weight of DOK5 is ,30 kDa. GAPDH is shown
as a loading control. The experiment was repeated twice with reproducible results. C. Production of DOK5 protein is induced by exogenous IGFBP-5.
Human skin fibroblasts were stimulated with recombinant IGFBP-5 (rBP5), and whole cell lysates were harvested. DOK5 production was examined by
immunoblotting. GAPDH is shown as a loading control. The experiment was repeated three times. D. Graphical presentation of the data shown in
panel C. *indicates p,0.05. E. Induction of DOK5 protein production is blocked by the Mek inhibitor (MEKi). Meki was administered after infection
with AdVs and levels of DOK5 examined by immunoblotting. GAPDH is shown as a loading control. Data shown are representative of two
independent experiments.
doi:10.1371/journal.pone.0087754.g001
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Statistical Analysis
Statistical comparisons were performed using the Mann-
Whitney U-test or one-way ANOVA as appropriate.
Results
DOK5 Expression is Upregulated by Endogenous and
Exogenous IGFBP-5 via MAPK
To delineate the pathways involved in IGFBP-5-induced
fibrosis, we examined the effect of IGFBP-5 on DOK5 levels. As
shown in Figure 1A and B, both DOK5 mRNA and protein levels
are increased in IGFBP-5-expressing human skin fibroblasts
compared with control AdV-treated fibroblasts. Exogenous
administration of physiological concentrations of IGFBP-5 also
induced the expression of DOK5 (Figure 1C and D). DOK5
upregulation was regulated by MAPK activation since the MEK
inhibitor U0126 abrogated IGFBP-5 induction of DOK5
(Figure 1E).
DOK5 Localizes to the Nucleus
To identify the intracellular localization of DOK5, we detected
DOK5 following its overexpression as well as its induction by
Figure 2. DOK5 localizes to the nucleus. A. Confirmation of DOK5 expression. Expression of DOK5 was confirmed by immunoblotting following
transient transfection of COS7 cells with DOK5-pAdlox or control-pAdlox plasmids. GAPDH is shown as a loading control. Data were confirmed in an
additional two experiments. B. DOK5 translocates to the nucleus. DOK5 localization in COS7 cells treated as in A using immunofluorescence. DOK5 is
shown in red and nuclei stained with DAPI appear blue. Merged signal appears purple. Indicated times reflect hours post-transfection. Magnification,
800x. C. Nuclear DOK5 levels are increased by endogenous IGFBP-5. Lysates of primary human fibroblasts infected with adenovirus (AdV) were
fractionated into cytoplasmic and nuclear fractions and induction of DOK5 was examined using immunoblotting. b-actin and Histone H3 are shown
as loading control for cytoplasmic and nuclear fractions, respectively. Findings were confirmed in two independent experiments. D. Nuclear DOK5
levels are induced by exogenous IGFBP-5. Cytoplasmic fractions of primary human fibroblasts treated with recombinant IGFBP-5 (rBP5) were
harvested and induction of DOK5 was examined. Histone H3 was used as a loading control. Findings were confirmed in two independent
experiments.
doi:10.1371/journal.pone.0087754.g002
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IGFBP-5. A DOK5-expressing pAdlox construct was generated
and DOK5 expression confirmed via transient transfection of
COS7 cells with DOK5-pAdlox vector (Figure 2A). Using this
vector, intracellular localization was examined by immunocytos-
taining. DOK5 localized to cell nuclei (Figure 2B) suggesting that
the vector-encoded DOK5 retained its ability to translocate to the
nucleus. We then examined intracellular localization of DOK5
following induction by IGFBP-5 in cytoplasmic and nuclear
extracts of cultured primary human skin fibroblasts infected with
IGFBP-5 AdV, IGFBP-3 AdV as a related control protein or
control AdV. DOK5 was detectable in cytoplasmic fractions under
all treatment conditions, but DOK5 levels were only increased in
the nuclear fraction (Figure 2C) of IGFBP-5 expressing fibroblasts.
Similar results were obtained in fibroblasts treated with recombi-
nant IGFBP-5 (Figure 2D). Thus, both endogenous and exogenous
IGFBP-5 induce DOK5 expression and nuclear localization.
DOK5 Production is Increased In Vivo by IGFBP-5
To determine whether IGFBP-5 also induces DOK5 in vivo,
IGFBP-5 AdV or control AdV, were administered to mouse lung
Figure 3. DOK5 is upregulated in lung and skin tissues
engineered to express IGFBP-5 and localizes to cell nuclei
in vivo. A. DOK5 expression was examined in skin (left panel) and lung
(right panel) tissues of C57BL6/J mice treated with control or IGFBP-5
expressing adenovirus (control AdV and IGFBP-5 AdV, respectively).
DOK5-expressing cells appear brown following AEC staining. Magnifi-
cation, 800x. Data are representative of skin and lung tissues from 2
mice/group. B. Graphical presentation of data shown in A using 8 fields
per treatment condition. Y axis shows the number of DOK5-positive
cells counted at a magnification of 400X. Bars denote the mean and
error bars denote SD.
doi:10.1371/journal.pone.0087754.g003
Figure 4. DOK5 expression increases dermal thickness. A.
Representative results of organ culture of human skin engineered to
express IGFBP-5, DOK5, or control. DOK5 expression was examined in
human skin treated with control or IGFBP-5 expressing adenovirus
(control AdV and IGFBP-5 AdV, respectively). DOK5-expressing cells
were shown in red using AEC staining. Magnification, 800x. Results are
representative of three experiments. B. DOK5 triggers dermal fibrosis.
Dermal thickness and collagen content as assessed by Masson
Trichrome are increased in DOK5-treated human skin. Magnification,
40x. Findings were replicated using skin from two different donors. C.
DOK5 induces a significant increase in dermal thickness. Dermal
thickness was measured in human skin and represents the average of
4 experiments. Values shown represent mean and SD. *P,0.008.
doi:10.1371/journal.pone.0087754.g004
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or skin and DOK5 detected using IHC. DOK5 localized to
cellular nuclei in skin and lung mouse tissues engineered to express
IGFBP-5 as shown in Figure 3A. Based on morphology, DOK5
was detectable in fibroblasts in skin tissues, and in cellular
infiltrates such as mononuclear cells and in epithelial cells in lung
tissues. The number of DOK5 positive cells was increased by
IGFBP-5 in both skin and lung (Figure 3B).
DOK5 Induces a Fibrotic Phenotype Ex Vivo in Human
Skin
We examined whether DOK5 can directly induce a fibrotic
phenotype in a human tissue and thus serve as an intermediate for
IGFBP-5. We used human skin engineered to express DOK5 or
IGFBP-5 using DOK5 AdV and IGFBP-5 AdV, respectively [7].
Figure 5. DOK5 mRNA and protein levels are increased in lung and skin tissues of SSc patients. A. DOK5 protein is increased in lung
tissues of SSc patients. DOK5 protein was detected in total lung tissue homogenates of patients with SSc and healthy controls using immunoblotting.
B. DOK5 protein levels are significantly elevated in SSc lung tissues. Data presented show average signal intensity of DOK5 in lung homogenates from
3 patients with SSc and 3 healthy controls. Protein levels were examined using immunoblotting and signals quantified with densitometry. *P,0.05. C.
Representative images of DOK5 in skin tissue from a patient with SSc and a normal control (NC). DOK5 was detected using immunohistochemistry.
Brown signal indicates DOK5. Arrows point to representative cells positive for DOK5. Sections were counter-stained with hematoxylin. Images are
representative of sections from three patients and three controls. Bar = 20 mm. Magnification, 400x. D. Localization of DOK5 and aSMA in SSc skin.
White color indicates merging of blue, red and green, and shows expression of DOK5 in nuclei. Images are representative of immunofluorescence
staining done on skin samples from two patients with SSc and two controls. Bar = 20 mm.
doi:10.1371/journal.pone.0087754.g005
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As shown in Figure 4A, DOK5 is expressed in dermal fibroblasts.
We then examined the ability of DOK5 to induce collagen
deposition and dermal thickening using Masson Trichrome
staining (Figure 4B). DOK5 induced significant skin thickening
similarly to IGFBP-5 (Figure 4C) [7]. These results suggest that
DOK5 can directly induce fibrosis in human skin.
Figure 6. DOK5 mRNA and protein levels are increased in cultured dermal fibroblasts of patients with SSc. A. DOK5 mRNA levels are
increased in dermal fibroblasts of patients with SSc compared to fibroblasts from their healthy twin. Expression of DOK5 was examined using RT-PCR.
Representative results of samples from 2 pairs of identical twins discordant for SSc are shown. B. DOK5 mRNA levels are significantly higher in SSc
fibroblasts. Graphical presentation is from data obtained from dermal fibroblasts of 5 pairs of twins discordant for SSc. P,0.05 by one-way ANOVA. C.
Representative results of DOK5 protein detected by immunofluorescence in control and SSc fibroblasts. Magnification, 400x. D. DOK5 protein levels
are significantly increased in SSc dermal fibroblasts. Levels of DOK5 protein in dermal fibroblasts from 3 controls and 3 patients with SSc were
detected by immunocytochemistry and fluorescence intensity measured using Metamorph. *P,0.05. E. DOK5 protein levels are increased in SSc
fibroblasts. DOK5 proteins were detected by immunoblotting in skin fibroblasts of 4 twins discordant for SSc. F. DOK5 protein levels are significantly
higher in SSc fibroblasts. Graphical presentation of immunoblotting results shown in panel E using fibroblasts from 4 patients with SSc and their
healthy twins. *P,0.008. The twin cohort was previously described [22].
doi:10.1371/journal.pone.0087754.g006
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DOK5 Protein Levels are Increased in Lung and Skin
Tissues of SSc Patients
We previously reported increased IGFBP-5 in fibrotic lung and
skin of patients with SSc and lung tissues of patients with IPF [2–4]
and that IGFBP-5 can induce fibrosis in vitro and in vivo [3,4].
Since DOK5 is induced by IGFBP-5, we hypothesized that DOK5
may be increased in SSc tissues and primary fibroblasts. DOK5
was detected in lung homogenates by immunoblotting (Figure 5A)
and its levels were significantly higher in lung tissues of SSc
patients compared to those from normal controls (Figure 5B). In
addition to fibrotic lung tissues of patients with SSc, increased
DOK5 levels were also noted in SSc skin, where DOK5 was
detected in fibroblasts, endothelial cells, and some infiltrating
immune cells (Figure 5C).
Co-localization of DOK5 and aSMA was examined. As shown
in Figure 5D, DOK5 was expressed in aSMA-expressing
fibroblasts and infiltrating mononuclear cells surrounding blood
vessels. DOK5 was detected in cell nuclei in vivo (inset).
Increased DOK5 expression in SSc dermal fibroblasts was
confirmed using skin fibroblasts from twins discordant for SSc. As
shown in Figure 6A and B, DOK5 mRNA was increased in
fibroblasts from the clinically affected skin of the SSc patients
compared with their own uninvolved skin fibroblasts or those of
their healthy twin. DOK5 protein levels were also significantly
increased in SSc dermal fibroblasts compared with fibroblasts
from the patients’ healthy twins when detected using immunocy-
tochemistry (Figure 6C and D) or immunoblotting of cell
homogenates (Figure 6E and F).
Discussion
We previously reported increased expression of IGFBP-5 in
primary dermal fibroblasts of patients with SSc [2], and increased
levels of IGFBP-5 mRNA and protein in lung tissues of patients
with IPF and SSc [3] and in primary fibroblasts cultured from
these tissues [3,4]. Interestingly, IGFBP-5 induces ECM produc-
tion and fibrosis in vitro [3] in vivo [4,5], and ex vivo [7]. In this
study, we identified a new signaling molecule, DOK5, downstream
of IGFBP-5-induced fibrosis. We showed that DOK5 was
upregulated by endogenous and exogenous IGFBP-5 stimulation
via MAPK signaling, and expression of DOK5 increased dermal
thickness of human skin similarly to IGFBP-5. Also, DOK5 levels
were increased in cultured fibroblasts and in myofibroblasts in
tissues of patients with SSc. Thus, these results suggest that
upregulated expression of DOK5 is also associated with the
development of fibrosis and the pathogenesis of SSc.
DOK5 is one of seven proteins in the mammalian Dok protein
family [8]. The Dok proteins are structurally similar with
conserved amino-terminal pleckstrin homology and phosphotyr-
osine-binding domains followed by Src homology 2 (SH2) target
motifs in the COOH-terminal region, suggesting they may have
adaptor function. Since they can also recruit and promote the
assembly of specific signal transduction molecules via these motifs,
DOK proteins may play an important role in the transduction of
intracellular signals. Moreover, DOK proteins are also known as
insulin receptor substrates, and serve as substrates for various
protein tyrosine kinases. For example, DOK5 is reported as a
substrate for the c-Ret receptor tyrosine kinase [11] and
tropomyosin-related kinase (Trk) family receptors (TrkB/C) [10].
Functionally, DOK5 is involved in neuronal [11] and cardiomy-
ocyte differentiation [12]. We show that DOK5 also induces a
fibrotic phenotype. Since DOK4, 5, and 6 are preferentially
expressed in non-hematopoietic cells as signal activation adaptors
[10,11], whereas DOK1, 2, and 3 are mainly expressed in
hematopoietic cells as signal inhibitors [8], our results suggest that
DOK5 promotes fibrotic signals in non-hematopoietic cells such as
fibroblasts. DOK5-induced fibrosis was a little more pronounced
than that of IGFBP-5. The effect of the two proteins is not
significantly different and may result from a potentially more
efficient adenoviral infection with the DOK5 Adv. Another
potential explanation is that IGFBP-5 likely induces expression of
mediators of fibrosis such as DOK5 as well as components of a
regulatory network that dampen its effects, whereas DOK5
expression may not induce the same negative feedback pathways
as IGFBP-5 and/or may not activate them to the same extent.
As shown in this study, induction of DOK5 by IGFBP-5
requires extracellular MAPK activation. We previously reported
that early growth response protein-1 (Egr-1) was also upregulated
by IGFBP-5 via MAPK signaling, and MAPK activation mediated
the induction of ECM production [14]. Moreover, this effect was
independent of IGF-I, suggesting a direct effect of IGFBP-5. Our
current results suggest that increased production of DOK5 is
regulated in a similar manner to Egr-1. DOK5 is also reported as a
substrate for insulin and IGF receptors [9]. Serum IGF-I levels are
elevated in patients with diffuse cutaneous SSc compared with
limited cutaneous SSc, and also in patients with pulmonary fibrosis
[17]. Furthermore, both IGF-I [18] and IGF-II [19] enhance
collagen synthesis in fibroblasts leading to fibrosis. Thus, it is
possible that upregulated DOK5 in SSc fibroblasts also contributes
to IGF-mediated induction of fibrosis. It is also conceivable that
upregulated expression of DOK5 contributes to the development
of a fibrotic phenotype directly downstream of IGFBP-5 and
possibly other members of the IGF family.
Interestingly, DOK5 was described as a membrane-associated
adaptor protein [20]. However, in our study, DOK5 induced by
IGFBP-5 translocated to the nucleus. Also, DOK5 was in the lipid
raft fractions of IGFBP-5-expressing fibroblasts (data not shown).
Since we previously reported that IGFBP-5 translocates from the
plasma membrane to the nucleus via caveolae [21], it is likely that
DOK5 translocates with IGFBP-5 to the nuclear compartment.
This is further supported by a report showing DOK5 to be
involved in the translocation of Foxa1 from the nucleus to the
cytoplasm [12]. Our findings suggest that IGFBP-5 stimulation
directs DOK5 translocation from the cytoplasm to the nucleus.
In summary, our findings show that IGFBP-5 induces its pro-
fibrotic effects, at least in part, via DOK5. Furthermore, IGFBP-5
and DOK5 are both increased in SSc fibroblasts and tissues, and
may thus be acting in concert to promote fibrosis. DOK5 may be a
novel regulator of ECM production and can exert its effects
independently of IGFBP-5.
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